Inhibition of CD11b/CD18 desialylation may represent a promising therapeutic strategy for reducing dysregulated PMN influx and associated mucosal tissue damage in chronic inflammatory disorders, including COPD and IBD. Here, ITGB2 is linked to inflammatory bowel disease.